Evidence map›Paper›PMID 32343052›Full record

ArticleCancer medicine2020

FAM225A facilitates colorectal cancer progression by sponging miR-613 to regulate NOTCH3.

Xuexiu Zhang, Haoling Shi, Jianning Yao, Yanle Li, Bing Gao, Yanzhen Zhang, Chunfeng Wang, Haining Zhou, Lianfeng Zhang

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.8field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Components ofJournal of oncology · 2022
    Article
  7. Prognosis model of colorectal cancer patients based onJournal of gastrointestinal oncology · 2021
    Article
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Xuexiu ZhangDepartment of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Haoling ShiDepartment of General Surgery, The First People Hospital of Zhengzhou, Zhengzhou, China.
Jianning YaoDepartment of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yanle LiDepartment of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Bing GaoDepartment of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yanzhen ZhangDepartment of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Chunfeng WangDepartment of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Haining ZhouDepartment of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Lianfeng ZhangDepartment of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.ORCID 0000-0002-0017-7151
First Affiliated Hospital of Zhengzhou University · CNZhengzhou People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) is a fatal disease ranking the third among the commonplace cancer types around the world. It is extremely significant to exploit effective treatments against CRC. FAM225A was proved to influence cell progression and forecast unfavorable prognosis in nasopharyngeal carcinoma. The role and function mechanism of FAM225A are still unclear in CRC. In this research, FAM225A was discovered presenting much higher expression in CRC tissues and cell lines. In addition, depleting FAM225A was capable of inhibiting cell proliferation, migration, and epithelial-to-mesenchymal transition (EMT) progress, and enhancing cell apoptosis ability. Furthermore, miR-613 exerted important effects as a mediator between FAM225A and NOTCH3. NOTCH3 was negatively correlated with miR-613, whereas was positively associated with FAM225A. Via competitively binding with miR-613, FAM225A positively regulated NOTCH3 expression. FAM225A facilitated CRC occurrence and development through positively regulating NOTCH3 expression by binding with miR-613. In a word, FAM225A/miR-613/NOTCH3 axis may play a tumor-facilitator in CRC cell progression. These data manifested the pivotal effect of FAM225A/miR-613/NOTCH3 pathway in CRC cell proliferation, apoptosis, and migration process. The findings may provide some theoretical basis and different perspective for CRC treatment.

Indexed as

Gene Expression Regulation, NeoplasticAmyloidogenic ProteinsApoptosisBiomarkers, TumorCell MovementCell ProliferationColorectal NeoplasmsHumansNerve Tissue ProteinsPrognosisReceptor, Notch3Survival RateTumor Cells, CulturedAmyloidogenic ProteinsBiomarkers, TumorFAM222A protein, humanNerve Tissue ProteinsNOTCH3 protein, humanReceptor, Notch3colorectal cancerFAM225AmiR-613NOTCH3

Identifiers

PMID32343052
PMCPMC7300395
OpenAlexW3018550950

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.